{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:32:24Z","timestamp":1793367144984,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.annonc.2026.09.011","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:10:32Z","timestamp":1790694632000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2675-5095","authenticated-orcid":false,"given":"D.F.","family":"McDermott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-9105","authenticated-orcid":false,"given":"S.","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-863X","authenticated-orcid":false,"given":"F.","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-0965","authenticated-orcid":false,"given":"S.S.","family":"Tykodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tomczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6903-5357","authenticated-orcid":false,"given":"G.A.","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.G.","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"Kochenderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Gafanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cristescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Markensohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8835-7714","authenticated-orcid":false,"given":"M.","family":"Nebozhyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Rodriguez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Burgents","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.annonc.2026.09.011_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN guidelines\u00ae insights: kidney cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.011_bib3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.011_bib4","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.011_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2026.09.011_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.011_bib7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.011_bib8","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41591-025-03867-5","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial","volume":"31","author":"Rini","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2025.09.006","article-title":"Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial","volume":"37","author":"Motzer","year":"2026","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.011_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.annonc.2024.12.008","article-title":"Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial","volume":"36","author":"Choueiri","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.011_bib11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.23.01569","article-title":"Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III Study","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.011_bib12","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.011_bib13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.011_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2026.09.011_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.011_bib17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.20.02363","article-title":"Open-label, single-arm phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.09.011_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.011_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.011_bib20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"issue":"10189","key":"10.1016\/j.annonc.2026.09.011_bib21","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.011_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.011_bib23","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"issue":"6411","key":"10.1016\/j.annonc.2026.09.011_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.011_bib25","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-21-3329","article-title":"Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types","volume":"28","author":"Cristescu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.011_bib26","doi-asserted-by":"crossref","first-page":"P375","DOI":"10.1016\/j.annonc.2024.12.003","article-title":"Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma","volume":"36","author":"Motzer","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.09.011_bib27","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.011_bib28","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"issue":"36","key":"10.1016\/j.annonc.2026.09.011_bib29","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.2018.79.2259","article-title":"Renal cell carcinoma in the era of precision medicine: from molecular pathology to tissue-based biomarkers","volume":"36","author":"Signoretti","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib30","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1038\/s41467-020-17965-0","article-title":"A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response","volume":"11","author":"Hakimi","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.011_bib31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial","volume":"9","author":"Hakimi","year":"2019","journal-title":"Cancer Discov"},{"issue":"6377","key":"10.1016\/j.annonc.2026.09.011_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.annonc.2026.09.011_bib33","first-page":"2116","article-title":"PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer","volume":"13","author":"Santos","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"11","key":"10.1016\/j.annonc.2026.09.011_bib34","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"issue":"suppl 6","key":"10.1016\/j.annonc.2026.09.011_bib35","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.2023.41.6_suppl.608","article-title":"Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC)","volume":"41","author":"Choueiri","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.011_bib36","doi-asserted-by":"crossref","first-page":"S1012","DOI":"10.1016\/j.annonc.2024.08.1787","article-title":"1694MO Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): analysis from CheckMate 9ER","volume":"35","author":"Braun","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.10.014","article-title":"Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma","volume":"33","author":"Ho","year":"2015","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.juro.2015.07.113","article-title":"Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression","volume":"195","author":"Joseph","year":"2016","journal-title":"J Urol"},{"issue":"14","key":"10.1016\/j.annonc.2026.09.011_bib39","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176230","article-title":"Molecular analysis of primary and metastatic sites in patients with renal cell carcinoma","volume":"134","author":"Gulati","year":"2024","journal-title":"J Clin Invest"},{"issue":"18","key":"10.1016\/j.annonc.2026.09.011_bib40","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","article-title":"Molecular genetics of clear-cell renal cell carcinoma","volume":"32","author":"Brugarolas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.011_bib41","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41436-020-0801-x","article-title":"Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma","volume":"22","author":"Lasseter","year":"2020","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.09.011_bib42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eururo.2017.03.046","article-title":"Evolution of circulating tumor DNA profile from first-line to subsequent therapy in metastatic renal cell carcinoma","volume":"72","author":"Pal","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib43","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1038\/s41598-021-85099-4","article-title":"Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.annonc.2026.09.011_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_430734","article-title":"Update on biomarkers in renal cell carcinoma","volume":"44","author":"Saliby","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"25","key":"10.1016\/j.annonc.2026.09.011_bib45","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1200\/JCO.21.02938","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-naive patients with advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)","volume":"40","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.011_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004780","article-title":"Phase II study of nivolumab and salvage nivolumab\/ipilimumab in treatment-na\u00efve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)","volume":"11","author":"Atkins","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.011_bib47","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/2326-6066.CIR-17-0475","article-title":"The clinical activity of PD-1\/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma","volume":"6","author":"McKay","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annonc.2026.09.011_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.941835","article-title":"The role of immunotherapy in non-clear cell renal cell carcinoma","volume":"13","author":"Climent","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2026.09.011_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2318","article-title":"LBA75 Prospective randomised phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial","volume":"35","author":"Bergmann","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.09.011_bib50","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.011_bib51","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.09.011_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acr.2015.04.002","article-title":"Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment","volume":"128","author":"Parker","year":"2015","journal-title":"Adv Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2026.09.011_bib53","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1080\/0284186X.2022.2119100","article-title":"Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma","volume":"61","author":"Donskov","year":"2022","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib54","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/s41467-020-15959-6","article-title":"PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.annonc.2026.09.011_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma","volume":"10","author":"Motzer","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.annonc.2026.09.011_bib56","doi-asserted-by":"crossref","first-page":"33614","DOI":"10.18632\/oncotarget.16833","article-title":"Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications","volume":"8","author":"Hahn","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3892\/mco.2020.2178","article-title":"Circulating tumor DNA analysis of metastatic renal cell carcinoma","volume":"14","author":"Zhang","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"15","key":"10.1016\/j.annonc.2026.09.011_bib58","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/24684570241303346","article-title":"Liquid biopsy for renal cell carcinoma: a comprehensive review of techniques, applications, and future prospects","volume":"8","author":"Jani","year":"2024","journal-title":"Kidney Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2026.09.011_bib60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","article-title":"Multi-stage mechanisms of tumor metastasis and therapeutic strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.annonc.2026.09.011_bib61","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.trecan.2022.03.002","article-title":"Ecology and evolution of dormant metastasis","volume":"8","author":"Blasco","year":"2022","journal-title":"Trends Cancer"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.09.011_bib62","article-title":"ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial","volume":"44","author":"Choueiri","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.09.011_bib63","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1158\/1078-0432.CCR-26-0216","article-title":"Dissecting the tumor microenvironment to identify biomarkers of outcome to anti-PD-1 therapy in clear cell renal cell carcinoma: analyses of the HCRN GU16-260 trial","volume":"32(16)","author":"El Ahmar","year":"2026","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426066561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:44:50Z","timestamp":1793364290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426066561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S0923753426066561"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.011","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}